ATLANTA, GA – – (Globe Newswire – February 5, 2026) – – A shareholder class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Ultragenyx’s expected results for its Phase III Orbit and Cosmic Studies, including setrusumab’s potential and the risks inherent in the study protocols put forth.

If you purchased Ultragenyx shares between August 3, 2023 and December 26, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/ultragenyx-pharmaceutical/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is April 6, 2026.